Multiple stages of carcinogenesis in colon cancer encompass subpopulations of cancer stem cells (CSC), responsible for tumor cell transformation, growth and proliferation. CD44 and CD166 proteins are CSC markers associated with cell signaling, adhesion, migration, metastasis and lymphocytic response. The expression of CSC may be modulated by some factors, such as the KRAS gene mutation.
OBJECTIVE:
Correlate the expression of CD44 and CD166 markers in metastatic colon adenocarcinoma and KRAS mutation status (wild-type/mutated) with clinical pathological features and patients' outcome.
MATERIAL AND METHODS:
Fifty-eight samples of tumor tissue samples of metastatic colon adenocarcinoma were collected from patients treated with CapeOx at the HCFMRP-USP Clinical Oncology Service. Clinical and survival data were collected from medical records. KRAS status was determined by the polymerase chain reaction (PCR) technique, and analysis of immunohistochemical expression of CD44 and CD166 proteins was performed by tissue microarray.
RESULTS:
The expression of CD44 and CD166 were positive in 41% and 43% of patients, respectively, and mutated KRAS was detected in 48% of patients. A significant association was found between CD166 and CD44 expression (p= 0.016), mainly in the wild-type KRAS group (p= 0.042) and patients over 65 years (p= 0.001). CD44-positive patients had 3.7-fold and 5.3-fold greater risk of liver metastasis and lung metastasis, respectively(p< 0.01), compared with CD44-negative patients. CD166-negative patients had 2.7 greater risk of lymph node involvement (0.03), compared with CD166-positive patients. KRAS mutation increased the risk of liver metastasis by 8 times (p< 0.01), and the risk of lung metastasis by 5 times(p= 0.04) in CD44-positive patients. KRAS mutation increased the risk of lymph node involvement by 8 times in CD166-negative patients (p= 0.0007).
CONCLUSION:
An association between CD44 and CD166 expression was demonstrated in this study. Analysis of KRAS mutation combined with immunohistochemical expression of CD44 and CD166 identified subgroups of patients with colon adenocarcinoma at higher risk of lymph node involvement by the tumor and development of liver and lung metastasis.
SiegelR., NaishadhamD. and JemalM.A.A., Cancer Statistics, Ca cancer j clin63 (2013), 11-30.
2.
FearonE.R. and VogelsteinB., A genetic model for colorectal tumorigenesis, Cell61 (1990), 759-67.
3.
CroceC.M., Oncogene and cancer, N Engl J Med358 (2008), 204-11c.
4.
FerreiraC.G. and RochaJ.C., Carcinogênese - aspectos moleculares, in: Oncologia - aspectos moleculares, Atheneu Ed, São Paulo, 2004.
5.
SanfordD., MarkowitzS.D. and BertagnolliM.M., Molecular Basis of Colorectal Cancer, N Engl J Med361 (2009), 2449-60.
6.
RoyS. and MajumdarA.P.N., Signaling in colon cancer stem cells, Journal of Molecular Signaling (2012), 7-11.
7.
VitianiL.R., FabriziE., PalioE. and MariaR., Colon cancer stem cells, J Mol Med87 (2009), 1097-1104.
8.
QuinlanM. and SettlemanJ., Explaining the preponderance of Kras mutations in human câncer. An isoform-specific function in stem cell expansion, Cell Cycle7(10) (2008), 1322-35.
9.
SuzukiA., SekiyaS., GunshimaE., FujiiS. and TaniguchiH., EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture, Laboratory Investigation90 (2010), 1425-1436.
10.
FengY., DaiX., LiX., WangH., LiuJ., ZhangJ., DuY. and XiaL., EGF signaling pathway regulates colon cancer stem cell proliferation and apoptosis, Cell Prolif45 (2012), 413-419.
11.
FengY., BommerG.T., ZhaoJ., GreenM., SandsE., ZhaiY., BrownK., BurberryA., ChoK.R. and FearonE.R., Mutant Kras Promotes Hyperplasia and Alters Differentiation in the Colon Epithelium But Does Not Expand the Presumptive Stem Cell Pool, Gastroenterology141(3) (2011), 1003-13.
12.
MilanoG., Etienne-GrimaldiM.C. and DahanL., Epidermal growth factor receptor (EGFR) status and Kras mutations in colorectal cancer, Ann Oncol19 (2008), 2033-8.
13.
De RoockW., JonkerD.J. and Di NicolantonioF., Association of KRAS p.G13D Mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA304(16) (2010), 1812-20.
14.
LanganR.C., MullinaxJ.E., RayS., RaijiM.T., SchaubN., XinH.W., KoizumiT., SteinbergS.M., AndersonA., WiegandG., ButcherD., AnverM., BilchikA.J., StojadinovicA., RudlofU. and AvitaI., A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers, Journal of Cancer3 (2012), 231-40.
15.
HorstD., KrieglL., EngelJ., KirchnerT. and JungA., Prognostic significance of the Cancer stem cell markers CD133, CD44 and CD166 in colorectal cancer, Cancer Investigation27 (2009), 844-50.
16.
ChoiD., LeeH.W., HurK.Y., KimJ.J., ParkG.S., JangS.H., SongY.S., JangY.K. and PaikS.S., Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma, World J Gastroenterol15(18) (2009), 2258-64.
17.
WeichertW., KnöselT., BellachJ., DietelM. and KristiansenG., ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival, J Clin Pathol57 (2004), 1160-64.
18.
NganN.Y., YamamotoI., SeshimoI., EzumiK., TerayamaM., HemmiH., TakemasaI., IkedaM., SekimotoM. and MondenM., Multivariate Analysis of Adhesion Molecules Expression in Assessment of Colorectal Cancer, Journal of Surg Oncol95 (2007), 652-62.
19.
American Joint Committee on Cancer - AJCC. Cancer Staging Handbook, 7th edition. Springer, New York, 2009.
20.
FangY.J., ZhangL., WuX.J., LuZ.H., LiJ.B., OuQ.J., ZhangM.F., DingP.R., PanZ.Z. and WanD.S., Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer, Tumor Biol33 (2012), 1907-14.
21.
TachezyT., ZanderH., GebauerF., MarxA., KaifiJ.T., IzbickiJ.R. and BockhornM., Activated leukocyte cell adhesion molecule (CD166) prognostic power for colorectal cancer patients, J Surg Res177(1) (2012), 15-20.
22.
ShafaeiS., SharbatdaranM., KamraniG. and KhafriS., The association between CD166 detection rate and clinicopathologic parameters of patients with colorectal cancer. Caspian J Intern Med4 (2013), 768-72.
23.
LugliA., IezziG., MuraroM.G., MeleV., TornilloL., SpagnoliG., TerraccianoL. and ZlobecI., Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer, Br J Cancer27 (2010), 382-90.
24.
BurkhardtM., MayordomoE., WinzerK.J., FritzscheF. and GansukhT., Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer, J Clin Pathol59 (2006), 403-09.
25.
Van den BrandM., TakesR.P., Blokpoel-deRuyterM., SlootwegP.J. and van KempenL.C., Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma, Oral Oncol46 (2010), 393-98.
26.
NiC., ZhangZ., ZhuX., LiuY., QuD., WuP., HuangJ. and XuA., Prognostic Value of CD166 Expression in Cancers of the Digestive System: A Systematic Review and Meta- Analysis, PLoS One5 (2013), 70958.
27.
BhaumikB., YingjieY.U., JianhuaD.U., PhillipA. and MajumdarA., Age-Related Increase in Colorectal Cancer Stem Cells in Macroscopically Normal Mucosa of Patients with Adenomas: A Risk Factor for Colon Cancer, Biochem Biophys Res Commun16 (2009), 344-47.
28.
NautiyalJ., DuJ., YuY., KanwarS.S., LevE. and MajumdarA.P.N., EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine, Am J Physiol Gastrointest Liver Physiol302 (2012), 655-63.
29.
De VitaV.T., LawrenceT.S. and RosenbergS.A., Cancer Principles and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia, 2008.
30.
MargaretP., QuinlanM.P., QuatelaS.E., PhilipsM.R. and SettlemanJ., Activated Kras, but not Hras or Nras, may initiated tumors of Endodermal Origin via Stem Cell Expansion, Molecular and Cellular Biology28(8) (2008), 2659-74.
31.
MoonB., JeongW., ParkJ., KimT.l., MinD.S. and ChoiK., Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/β -Catenin Signaling, J Natl Cancer Inst106 (2014), 373.
32.
IshidaT., Immunohistochemical Expression of the CD44 Variant 6 in Colorectal Adenocarcinoma, Jpn J Surg30 (2000), 28-32.
33.
DallasM.R., LiuG., ChenW., ThomasS.N., WirtzD., HusoD.L. and KonstantopoulosK., Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis, FASEB J26(6) (2012), 2648-56.
34.
JothyS., CD44 and its partners in metastasis, Clinical & Experimental Metastasis20 (2003), 195-201.
35.
EikiciS., AyhanA. and KendiS., Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score, J Urol167 (2002), 2037-41.
36.
ChoiS.H., TakahashiK., EtoH., YoonS.S. and TanabeK.K., CD44s expression in human colon carcinomas influences growth of liver metastases, Int J Cancer85 (2000), 523-26.
37.
AndreyevH.J.N., NormanA.R. and CunninghamD., Kirsten ras mutation in patients with colorectal cancer: the multicenter ``RASCAL'' study, J Nat Cancer Inst90(9) (1998), 675-84.
38.
CejasP., GomezM.L., AguayoC., MaderoR., CarpenJ.C., IniestaC.B.B., BarriusoJ., GarcıaV.M., LarrauriJ., LopezR., CasadoH., BaronM.G. and FeliuJ., KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis, PLoS ONE4(12) (2009), e8199.
39.
LiZ., ChenY., WangD., WangG., HeL. and SoJ., Detection of Kras Mutations and Their Associations with Clinicopathological Features and Survival in Chinese Colorectal Cancer Patients, J Int Med Res40 (2012), 1589-98.
40.
NashG.M., GimbelM., ShiaJ., NathansonD.R., NdubuisiM.I., ZengZ.S., KemenyN. and PatyP.B., KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases, Ann Surg Oncol17 (2010), 572-78.
41.
HanahanD. and WeinbergR.A., The Hallmarks of Cancer, Cell100 (2000), 57-70.
42.
HanahanD. and WeinbergR.A., Hallmarks of Cancer: The Next Generation, Cell4(144) (2011), 646-74.
43.
KellyH. and GolbergR.M., Systemic therapy for metastatic colorectal cancer: current options, current evidence, J Clin Oncol23 (2005), 4553-60.
44.
NHI consensus conference. Adjuvant therapy for patients with colon and rectal cancer, JAMA264(11) (1990), 1444-50.
45.
GarrityM.M., BurgartL.J., MahoneyM.R. and WindschitlH.E., Prognostic value of proliferation, apoptosis, defective DNA mismatch repair and p53 overexpression in patients with resected Dukes B2 or C colon cancer: A North Central Cancer Treatment Group Study, J Clin Oncol22(9) (2004), 1572-82.
